Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

NCT03545035 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT03545035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03545035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Observational
Overall status
Completed
Start date
February 6, 2019
Completion date
October 28, 2020
Enrollment
104 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia